Commentary on black cohosh for the treatment of menopausal symptoms

Menopause

Volumn 15, Issue 5, 2008, Pages 819-820

  Mello, Nancy K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; OPIATE RECEPTOR; PLANT EXTRACT;

CIMICIFUGA RACEMOSA; CLINICAL TRIAL; EDITORIAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; LIVER TOXICITY; MENOPAUSAL SYNDROME; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; THERAPY EFFECT; TREATMENT DURATION; BRAIN; CIMICIFUGA; DRUG EFFECT; FEMALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NOTE; PHYTOTHERAPY; PULSATILE FLOW; SECRETION;

BRAIN; CIMICIFUGA; FEMALE; HOT FLASHES; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; POSTMENOPAUSE; PULSATILE FLOW; RECEPTORS, OPIOID;

EID: 58249093168     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318182d367     Document Type: Editorial

References (24)

1. IOM. Complementary and Alternative Medicines in the United States. Executive Summary. Institute of Medicine. Washington, DC: National Academy of Sciences, 2005.
2. Reame NE, Lukacs JI, Padmanabhan V, Eyvazzadeh A, Smith Y, Zubieta JK. Black cohosh has a central opioid activity in postmenopausal women: evidence from naloxone blockade and PET neuroimaging studies. Menopause 2008;15:832-840.
3. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-813.
4. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15:51-58.
5. Pockaj B, Gallagher J. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC. J Clin Oncol 2006;24:2836-2841.
6. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869-879.
7. Chow EC, Teo M, Ring JA, Chen JW. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust 2008;188:420-422.
8. Joy D, Joy J, Duane P. Black cohosh: a cause of abnormal postmenopausal liver function tests. Climacteric 2008;11:84-88.
9. Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl 2006;12:989-992.
10. Mahady GB, Dog TL, Barrett ML, et al. United States Pharmacopoeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008;15:628-638.
11. Mahady GB. Black cohosh (Actaea-Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 2005;4:177-184.
12. Casper RF, Yen SS, Wilkes MM. Menopausal flushes: a neuroendocrine link with pulsatile luteinizing hormone secretion. Science 1979;205:823-825.
13. Nelson HD. Menopause. Lancet 2008;371:760-770.
14. Yen SS, Tsai CC, Naftolin F, Vandenberg G, Ajabor L. Pulsatile patterns of gonadotropin release in subjects with and without ovarian function. J Clin Endocrinol Metab 1972;34:671-675.
15. Yen SSC. The human menstrual cycle: neuroendocrine regulation. In: Yen SSC, Jaffe RB, eds. Reproductive Endocrinology, 3rd ed. Philadelphia: WB Saunders, 1991:273-308.
16. Yen SSC. The human menstrual cycle: neuroendocrine regulation. In: Yen SSC, Jaffe RB, Barbieri RL, eds. Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 4th ed. Philadelphia: WB Saunders, 1999:191-217.
17. Yen SSC, Quigley ME, Reid RL, Ropert JF, Cetel NS. Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion. Am J Obstet Gynecol 1985;152:485-493.
18. Coiro V, Volpi R, Gramellini D, et al. Age-related decrease in the opioid control of LH secretion during reproductive years in normal women. Gynecol Obstet Invest 1997;43:162-165.
19. Genazzani AR, Gastaldi M, Bidzinska H, et al. The brain as a target organ of gonadal steroids. Psychoneuroendocrinology 1992;17:385-390.
20. Mendelson JH, Mello NK. Endocrine effects of opioid antagonists. In: Dean R, Bilsky E, Gastfriend D, Negus SS, eds. Opiate Receptors and Antagonists. New York: Humana Press, 2008. in press.
21. Xiao E, Luckhaus J, Niemann W, Ferin M. Acute inhibition of gonadotropin secretion by corticotropin-releasing hormone in the primate: are the adrenal glands involved? Endocrinology 1989;124:1632-1637.
22. Xiao E, Xia-Zhang L, Ferin M. Stress and the menstrual cycle: short-and long-term response to a five-day endotoxin challenge during the luteal phase in the rhesus monkey. J Clin Endocrinol Metab 1999;84:623-626.
23. Zubieta J-K, Bueller JA, Jackson LR, et al. Placebo effects mediated by endogenous opioid activity on μ-opioid receptors. J Neurosci 2005;25:7754-7762.
24. Smith YR. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 2006;26:5777-5785.